Filing
📈 Stocks
Corbus Pharmaceuticals Reports 5% Weight Loss in Phase 1b Obesity Trial
(just now)
Corbus Pharmaceuticals' oral obesity drug CRB-913 achieved 5.0% weight loss in a 12-week Phase 1b study, with the company now planning regulatory…